The soft tissue sarcoma market is projected to be worth over USD 420 million in 2030, claims Roots A

Recent advances in molecular biology have enabled researchers to develop a better understanding of the rare soft tissue sarcomas; as a result, a number of viable biological targets have been identified and are being investigated for therapeutic relevance

Roots Analysis has announced the addition of “Soft Tissue Sarcoma: Focus on Angiosarcoma, Chondrosarcoma, and Liposarcoma Market, 2021-2030” report to its list of offerings.

Soft tissue sarcoma is a rare form of cancer that usually originates in soft / connective tissues and most commonly affects the abdomen, arms, head, legs, neck and trunk of the individual. It is worth noting that, till date, many types (50+) of soft tissue sarcoma have been identified. However, since these tumors possess a large set of entities, their diagnosis is often difficult. At present, there is a growing need for effective and targeted treatment options.

To order this 130+ slides report, which features 80+ figures, please visit

Key Market Insights

70+ therapeutics have been / are being developed for the treatment of angiosarcoma, chondrosarcoma and liposarcoma
Nearly 95% of the aforementioned therapeutic candidates are under clinical evaluation. Further, two therapies, namely YONDELIS® and HALAVEN®, have been approved for the treatment of liposarcoma.

Around 65% of the therapeutics are being developed as small molecules
Majority (over 65%) of the abovementioned drugs have been / are being developed for administration via the oral route. Notably, about 60% of the soft tissue sarcoma targeting therapeutics have been / are being developed for use as the 1st line of treatment.

Leave a Reply

Your email address will not be published. Required fields are marked *